K Papamichael1, S Rakowsky2, C Rivera3, A S Cheifetz1, M T Osterman3. 1. Division of Gastroenterology, Center for Inflammatory Bowel Diseases, Harvard Medical School, Beth-Israel Deaconess Medical Center, Boston, MA, USA. 2. Department of Internal Medicine, Beth-Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA. 3. Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Abstract
BACKGROUND: Endoscopic and histologic healing are emerging as new therapeutic goals in ulcerative colitis (UC), as these endpoints are associated with less relapse, hospitalization and colectomy. AIM: To investigate the association of serum infliximab trough concentrations during maintenance therapy with endoscopic or histologic healing in UC. METHODS: In this multi-center retrospective cohort study, we included consecutive patients with moderate-to-severe UC on infliximab maintenance therapy who had an endoscopic evaluation and underwent therapeutic drug monitoring within three months of the colonoscopy, between February 2008 and March 2016. Per event analysis was performed. Endoscopic healing was defined as Mayo endoscopic sub-score of ≤1. Histologic healing was defined as no or only focal mild active inflammation. RESULTS: Seventy colonoscopies from 56 patients were evaluated. Infliximab trough concentrations (median [interquartile range]) were significantly higher in patients with endoscopic (11.3 [7.6-14.5] vs 6.3 [0-9.8] μg/mL, P < .001) or histologic (11.1 [6.7-14.5] vs 6.7 [0-9.9] μg/mL, P = .002) healing, respectively, compared to patients without healing. Receiver-operating characteristic analyses identified infliximab trough concentration thresholds of 7.5 (area under the curve [AUC]: 0.758) and 10.5 (AUC: 0.721) μg/mL to be associated with endoscopic and histologic healing, respectively. Multiple logistic regression analysis identified infliximab trough concentration ≥7.5 (P = .013; odds ratio [OR]: 4.3; 95% confidence intervals [CI]: 1.4-13.3) and ≥10.5 μg/mL (P = .013; OR: 3.8; 95% CI: 1.3-11) as independent factors associated with endoscopic and histologic healing, respectively. CONCLUSIONS: This study demonstrated that infliximab trough concentrations during maintenance therapy are associated with endoscopic and histologic healing in patients with UC.
BACKGROUND: Endoscopic and histologic healing are emerging as new therapeutic goals in ulcerative colitis (UC), as these endpoints are associated with less relapse, hospitalization and colectomy. AIM: To investigate the association of serum infliximab trough concentrations during maintenance therapy with endoscopic or histologic healing in UC. METHODS: In this multi-center retrospective cohort study, we included consecutive patients with moderate-to-severe UC on infliximab maintenance therapy who had an endoscopic evaluation and underwent therapeutic drug monitoring within three months of the colonoscopy, between February 2008 and March 2016. Per event analysis was performed. Endoscopic healing was defined as Mayo endoscopic sub-score of ≤1. Histologic healing was defined as no or only focal mild active inflammation. RESULTS: Seventy colonoscopies from 56 patients were evaluated. Infliximab trough concentrations (median [interquartile range]) were significantly higher in patients with endoscopic (11.3 [7.6-14.5] vs 6.3 [0-9.8] μg/mL, P < .001) or histologic (11.1 [6.7-14.5] vs 6.7 [0-9.9] μg/mL, P = .002) healing, respectively, compared to patients without healing. Receiver-operating characteristic analyses identified infliximab trough concentration thresholds of 7.5 (area under the curve [AUC]: 0.758) and 10.5 (AUC: 0.721) μg/mL to be associated with endoscopic and histologic healing, respectively. Multiple logistic regression analysis identified infliximab trough concentration ≥7.5 (P = .013; odds ratio [OR]: 4.3; 95% confidence intervals [CI]: 1.4-13.3) and ≥10.5 μg/mL (P = .013; OR: 3.8; 95% CI: 1.3-11) as independent factors associated with endoscopic and histologic healing, respectively. CONCLUSIONS: This study demonstrated that infliximab trough concentrations during maintenance therapy are associated with endoscopic and histologic healing in patients with UC.
Authors: Jean Frédéric Colombel; Paul Rutgeerts; Walter Reinisch; Dirk Esser; Yanxin Wang; Yinghua Lang; Colleen W Marano; Richard Strauss; Björn J Oddens; Brian G Feagan; Stephen B Hanauer; Gary R Lichtenstein; Daniel Present; Bruce E Sands; William J Sandborn Journal: Gastroenterology Date: 2011-06-30 Impact factor: 22.682
Authors: Maria Theresa Arias; Niels Vande Casteele; Séverine Vermeire; Anthony de Buck van Overstraeten; Thomas Billiet; Filip Baert; Albert Wolthuis; Gert Van Assche; Maja Noman; Ilse Hoffman; Andre D'Hoore; Ann Gils; Paul Rutgeerts; Marc Ferrante Journal: Clin Gastroenterol Hepatol Date: 2014-08-10 Impact factor: 11.382
Authors: Casper Steenholdt; Klaus Bendtzen; Jørn Brynskov; Ole Ø Thomsen; Mark A Ainsworth Journal: Am J Gastroenterol Date: 2014-05-06 Impact factor: 10.864
Authors: Shui-Long Wang; Linda Ohrmund; Scott Hauenstein; Jared Salbato; Rukmini Reddy; Patrick Monk; Steven Lockton; Nicholas Ling; Sharat Singh Journal: J Immunol Methods Date: 2012-06-09 Impact factor: 2.303
Authors: D Laharie; J Filippi; X Roblin; S Nancey; J-B Chevaux; X Hébuterne; B Flourié; M Capdepont; L Peyrin-Biroulet Journal: Aliment Pharmacol Ther Date: 2013-03-21 Impact factor: 8.171
Authors: Laurent Peyrin-Biroulet; Walter Reinisch; Jean-Frederic Colombel; Gerassimos J Mantzaris; Asher Kornbluth; Robert Diamond; Paul Rutgeerts; Linda K Tang; Freddy J Cornillie; William J Sandborn Journal: Gut Date: 2013-08-23 Impact factor: 23.059
Authors: Freddy Cornillie; Stephen B Hanauer; Robert H Diamond; Jianping Wang; Kezhen L Tang; Zhenhua Xu; Paul Rutgeerts; Séverine Vermeire Journal: Gut Date: 2014-01-28 Impact factor: 23.059
Authors: Jurij Hanžel; Nejc Sever; Ivan Ferkolj; Borut Štabuc; Nataša Smrekar; Tina Kurent; Matic Koželj; Gregor Novak; Griet Compernolle; Sophie Tops; Ann Gils; David Drobne Journal: United European Gastroenterol J Date: 2019-03-19 Impact factor: 4.623
Authors: Konstantinos Papamichael; Adam S Cheifetz; Gil Y Melmed; Peter M Irving; Niels Vande Casteele; Patricia L Kozuch; Laura E Raffals; Leonard Baidoo; Brian Bressler; Shane M Devlin; Jennifer Jones; Gilaad G Kaplan; Miles P Sparrow; Fernando S Velayos; Thomas Ullman; Corey A Siegel Journal: Clin Gastroenterol Hepatol Date: 2019-03-27 Impact factor: 11.382
Authors: Konstantinos Papamichael; Anna Juncadella; Danny Wong; Shana Rakowsky; Lindsey A Sattler; James P Campbell; Byron P Vaughn; Adam S Cheifetz Journal: J Crohns Colitis Date: 2019-08-14 Impact factor: 9.071
Authors: John L Lyles; Aditi A Mulgund; Laura E Bauman; Weizhe Su; Lin Fei; Deepika L Chona; Puneet Sharma; Renee K Etter; Jennifer Hellmann; Lee A Denson; Phillip Minar; Dana M Dykes; Michael J Rosen Journal: Inflamm Bowel Dis Date: 2021-03-15 Impact factor: 5.325
Authors: Britt Christensen; Stephen B Hanauer; Peter R Gibson; Jerrold R Turner; John Hart; David T Rubin Journal: J Crohns Colitis Date: 2020-10-05 Impact factor: 10.020